GlassScriptPhysician profile
Renee Nadal
NPI 1063775047
$1,120.17
in general payments reported to CMS, 2019-2025
13 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $175 · 2022: $155 · 2023: $199 · 2024: $423 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $511.81 | 2022-2024 | Farxiga, Wainua, Fasenra |
| Daiichi Sankyo INC. | $178.13 | 2021-2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.27 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $92.46 | 2021-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $65.76 | 2025 | |
| Scpharmaceuticals INC. | $39.87 | 2025 | |
| Alnylam Pharmaceuticals INC. | $28.15 | 2024 | Amvuttra |
| Akcea Therapeutics, INC. | $21.72 | 2021 | |
| Cvrx, INC. | $21.51 | 2024 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $15.07 | 2024 | Xarelto |
| Bridgebio Pharma, INC. | $14.89 | 2025 | Attruby |
| Kestra Medical Technology Services, INC. | $13.93 | 2024 | Assure Wcd |
| Pfizer INC. | $13.60 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Nadal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.